8-K: Invivyd Reports Preliminary Q3 Results, Withdraws Guidance, and Highlights Positive Clinical Data

Invivyd announced preliminary Q3 2024 results, including $9.3 million in PEMGARDA net product revenue, withdrew prior financial guidance due to an FDA warning, and released positive long-term clinical efficacy data for PEMGARDA.

Summary

• Invivyd reported preliminary third quarter 2024 net product revenue for PEMGARDA at $9.3 million.
• The company ended the third quarter with approximately $107 million in cash and cash equivalents.
• Invivyd expects to finish 2024 with $65 million or more in cash and cash equivalents.
• The company withdrew its previous revenue guidance of $150-200 million for 2024 due to a late-Q3 FDA warning about potential reduced activity of pemivibart.
• Invivyd is targeting near-term profitability in the first half of 2025.
• A new exploratory analysis from the CANOPY Phase 3 clinical trial showed PEMGARDA provided a 64% risk reduction in symptomatic COVID-19 over six months in immunocompetent participants, with an overall 76% reduction over 12 months.
• The 64% risk reduction occurred at approximately 7% of the average titers during the active dosing period.

Sentiment

Score: 6

Explanation: The sentiment is mixed. While the clinical data is positive and the company is targeting profitability, the withdrawal of revenue guidance and the FDA warning create uncertainty and concern.

Positives

• PEMGARDA demonstrated a 64% relative risk reduction in symptomatic COVID-19 over six months in immunocompetent participants, with an overall 76% reduction over 12 months.
• The company is targeting near-term profitability in the first half of 2025.
• Invivyd has $107 million in cash and cash equivalents at the end of Q3 2024.
• The company expects to have $65 million or more in cash and cash equivalents by the end of 2024.
• The company is confident in the commercial potential of PEMGARDA.
• The safety profile of pemivibart over the 12-month study period was reassuring with no new trends or safety signals observed.

Negatives

• Invivyd withdrew its prior 2024 revenue guidance of $150-200 million.
• The FDA issued a warning in late-Q3 2024 about potential reduced activity of pemivibart, impacting product growth.
• The FDA warning caused confusion among healthcare professionals and vulnerable populations.
• Anaphylaxis was observed in 4 participants in Cohort A of the CANOPY trial, with two reactions being life-threatening.

Risks

• The company's future financial performance is subject to uncertainties regarding market acceptance and sales of PEMGARDA.
• The FDA could revise or revoke the Emergency Use Authorization for PEMGARDA.
• The company faces risks related to the development and regulatory approval of its product candidates.
• There are risks associated with the variability of results in models used to predict activity against SARS-CoV-2 variants.
• The company relies on third parties for virus assay creation, product candidate testing, and clinical trials.
• The company's ability to achieve profitability is dependent on the growth of net product revenue and operational efficiencies.
• The company's ability to continue as a going concern is dependent on adequate funding.

Future Outlook

Invivyd is targeting near-term profitability in the first half of 2025 and expects ongoing commercial optimization to drive growth. The company also plans to provide a full data set from the CANOPY clinical trial in an upcoming scientific publication.

Management Comments

• Tim Lee, Chief Commercial Officer, stated they were thrilled to engage with healthcare professionals to alleviate confusion regarding PEMGARDA's antiviral activity.
• Marc Elia, Chairman of the Board, expressed confidence in the demand for PEMGARDA and the ability to return to strong product growth.
• Robert Allen, Ph.D., Chief Scientific Officer, commented on the high confidence in the clinical benefit of mAbs even at low serum concentrations.

Industry Context

This announcement comes at a time when there is a continued need for effective COVID-19 prevention and treatment options, particularly for vulnerable populations. The company's focus on developing monoclonal antibodies to address evolving viral threats aligns with the broader industry trend of leveraging advanced antibody engineering to combat infectious diseases.

Comparison to Industry Standards

• The 76% risk reduction in symptomatic COVID-19 over 12 months with PEMGARDA is a strong result compared to other preventative measures, such as vaccines, particularly in immunocompromised populations.
• The company's focus on low-dose, high-potency, long-acting mAbs is a novel approach that could offer advantages over existing treatments.
• The company's approach of using immunobridging to support the EUA for PEMGARDA is consistent with the approach used for other mAbs against SARS-CoV-2.
• The company's results are being compared to previous clinical trials of other COVID-19 PrEP candidate mAbs, which were performed in populations naive to vaccination or infection, highlighting the unique context of the current study.

Stakeholder Impact

• Shareholders may be concerned about the withdrawn revenue guidance and the FDA warning, but encouraged by the positive clinical data and path to profitability.
• Healthcare professionals may be reassured by the updated data on PEMGARDA's efficacy and safety.
• Immunocompromised individuals may benefit from the continued availability of PEMGARDA as a preventative option.
• Employees may be impacted by the company's focus on operational efficiencies.

Next Steps

• Invivyd will provide a further update on the Q3 2024 earnings call.
• The company expects to provide the full data set from the CANOPY clinical trial in an upcoming scientific publication.
• Invivyd will continue discussions with key leaders at the FDA.
• The company will continue to focus on commercial optimization to drive growth.

Key Dates

Keywords

PEMGARDA, COVID-19, monoclonal antibody, pre-exposure prophylaxis, clinical trial, FDA, revenue, profitability, immunocompromised, SARS-CoV-2